# Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

Source: https://onco.cc/trials/nct04050436/  
OnCo record `nct04050436` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Cemiplimab in cutaneous squamous cell carcinoma, run by Replimune, Inc., active and no longer recruiting.

## Summary

Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer is a phase 2 interventional study registered as NCT04050436 by Replimune, Inc., with 231 participants enrolled, started 2019-10-08 and due to reach its primary completion in 2025-09. Interventions recorded: Cemiplimab, RP1. Conditions listed: Cutaneous Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04050436
- Phase: 2
- Setting: A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
- Sponsor: Replimune, Inc.
- Enrolled: 231

## Sources

- ClinicalTrials.gov NCT04050436: https://clinicaltrials.gov/study/NCT04050436

## Connected records

- cancers: [Cutaneous squamous cell carcinoma](https://onco.cc/cancers/cutaneous-scc/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/)
- companies: [Replimune](https://onco.cc/companies/replimune/)

---
JSON: https://onco.cc/api/v1/entities/nct04050436.json